Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Immuneering (NASDAQ:IMRX) from a "sell" to a "hold" in a research note published Sunday.
• Analyst sentiment is mixed but leans positive — one Strong Buy, five Buy and one Sell produce a MarketBeat consensus of "Moderate Buy" with a consensus target price of $16.50.
• Shares opened at $5.56 (market cap ~$359.5M); the company reported Q1 EPS of ($0.18) beating estimates, analysts project ~-1.86 EPS for the year, and institutions own about 67.65% of the stock.

Immuneering (NASDAQ:IMRX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

Several other analysts have also recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Immuneering Trading Down 0.2%

Shares of NASDAQ IMRX opened at $5.56 on Friday. The stock has a market cap of $359.47 million, a price-to-earnings ratio of -4.03 and a beta of 0.43. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08. The company has a 50 day simple moving average of $5.21 and a two-hundred day simple moving average of $5.77.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.13. Analysts forecast that Immuneering will post -1.86 EPS for the current year.

Institutional Trading of Immuneering

A number of large investors have recently made changes to their positions in IMRX. Jane Street Group LLC purchased a new stake in shares of Immuneering during the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Immuneering during the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. purchased a new position in Immuneering in the third quarter valued at approximately $35,000. Future Financial Wealth Managment LLC purchased a new position in shares of Immuneering during the third quarter worth approximately $35,000. Finally, SummitTX Capital L.P. purchased a new position in shares of Immuneering during the fourth quarter worth approximately $69,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.